[Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis].
Eighteen patients with relapsed or refractory Hodgkin's disease (HD) have been treated with high-dose chemotherapy (BEAM regimen) followed by autologous peripheral stem cells and/or bone marrow rescue. There were no treatment-related deaths. Overall response rate was 82%. With a median follow-up of 10 months (3-24 months) overall survival and freedom from progression were 100 and 94% (95% confidence interval 58-97%), respectively. The use of peripheral stem cells in addition to bone marrow resulted in a significant shortening of the time to engraftment (p < 0.01). The BEAM regimen is an effective conditioning schedule which is well tolerated.
Ptuskin
V V
VV
Uss
A L
AL
Demina
E A
EA
Chervonobab
Iu V
IuV
Milanovich
N F
NF
Tupitsyn
N N
NN
Larionova
V B
VB
Batan
Z E
ZE
Kondrat'eva
N E
NE
Zmachinskiĭ
V A
VA
Andreeva
L A
LA
Snegir'
V M
VM
Mkheidze
D M
DM
Chimishkian
K L
KL
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012008:Recurrence; D012074:Remission Induction; D014182:Transplantation, Autologous
D003561:Cytarabine; D005047:Etoposide; D008558:Melphalan; D002330:Carmustine
Sverkhvysokodoznaia khimioterapiia s transplantatsieĭ autologichnykh kletok predshestvennikov gemopoéza u bol'nykh s prognosticheski neblagopriiatnym retsidivom i rezistentnym techeniem limfogranulematoza.